{"id":"dendritic-cell-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dendritic cells are harvested from the patient, loaded with tumor antigens or engineered to express tumor-associated peptides, and then reinfused to prime T-cell responses against cancer. This approach leverages the dendritic cells' natural role as antigen-presenting cells to generate cytotoxic T-lymphocyte responses that target malignant cells. The vaccine aims to convert a patient's own immune system into a therapeutic agent against their cancer.","oneSentence":"A dendritic cell vaccine that activates the patient's immune system to recognize and attack cancer cells by presenting tumor-associated antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:09:00.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication not publicly detailed for this Phase 3 program)"}]},"trialDetails":[{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":"Breast Cancer, Breast Cancer Female, Breast Cancer, Male","enrollment":31},{"nctId":"NCT04801147","phase":"PHASE1, PHASE2","title":"Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2010-06-26","conditions":"Glioblastoma","enrollment":76},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT06805305","phase":"PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2025-03-17","conditions":"Glioblastoma (GBM)","enrollment":180},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT03384914","phase":"PHASE2","title":"Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-02-19","conditions":"Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I","enrollment":119},{"nctId":"NCT04335890","phase":"PHASE1","title":"IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma","status":"COMPLETED","sponsor":"Hasumi International Research Foundation","startDate":"2020-09-24","conditions":"Melanoma, Uveal Metastatic","enrollment":17},{"nctId":"NCT06253494","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-14","conditions":"Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium","enrollment":60},{"nctId":"NCT05325632","phase":"PHASE2","title":"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-10-28","conditions":"HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT07288112","phase":"PHASE1, PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2026-02-23","conditions":"Refractory Melanoma","enrollment":35},{"nctId":"NCT02063724","phase":"PHASE1","title":"HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-10-01","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT06342908","phase":"PHASE1","title":"A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-06-14","conditions":"Diffuse Hemispheric Glioma, H3 G34-Mutant","enrollment":6},{"nctId":"NCT07412197","phase":"PHASE1, PHASE2","title":"Preventive Dendritic Cell Vaccination for Lynch Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2026-06","conditions":"Lynch Syndrome","enrollment":23},{"nctId":"NCT05799612","phase":"PHASE1","title":"Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-22","conditions":"Angiosarcoma","enrollment":""},{"nctId":"NCT04348747","phase":"PHASE2","title":"Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2022-12-19","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma","enrollment":23},{"nctId":"NCT00458536","phase":"PHASE1, PHASE2","title":"Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2004-10","conditions":"Renal Cancer","enrollment":38},{"nctId":"NCT07396090","phase":"NA","title":"Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-20","conditions":"Advanced Solid Tumor","enrollment":13},{"nctId":"NCT05504707","phase":"PHASE1","title":"DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-08-26","conditions":"Triple Negative Breast Cancer, HER2-negative Breast Cancer","enrollment":30},{"nctId":"NCT03059485","phase":"PHASE2","title":"DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-06-01","conditions":"Acute Myelogenous Leukemia","enrollment":82},{"nctId":"NCT07377435","phase":"PHASE1","title":"DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma","enrollment":25},{"nctId":"NCT06435351","phase":"EARLY_PHASE1","title":"Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-06-12","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":16},{"nctId":"NCT03334305","phase":"PHASE1","title":"Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-05-16","conditions":"Malignant Glioma, High Grade Glioma","enrollment":18},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT04989946","phase":"PHASE1, PHASE2","title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT07219147","phase":"PHASE1","title":"177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-05","conditions":"Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT04590872","phase":"PHASE1","title":"An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-06-16","conditions":"Type 1 Diabetes Mellitus","enrollment":6},{"nctId":"NCT01983748","phase":"PHASE3","title":"Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma","status":"COMPLETED","sponsor":"University Hospital Erlangen","startDate":"2014-08-05","conditions":"Uveal Melanoma","enrollment":200},{"nctId":"NCT07365280","phase":"PHASE2","title":"Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"ZSky Biotech Inc","startDate":"2026-01-09","conditions":"Glioblastoma","enrollment":78},{"nctId":"NCT00625755","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2002-12","conditions":"Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT00626860","phase":"PHASE1, PHASE2","title":"The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2000-07","conditions":"Metastatic Melanoma","enrollment":20},{"nctId":"NCT03679650","phase":"PHASE1","title":"Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-10-11","conditions":"Acute Myelogenous Leukemia","enrollment":28},{"nctId":"NCT07345208","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of ID vs IM Rabies Vaccine","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-12-15","conditions":"Rabies","enrollment":90},{"nctId":"NCT05378464","phase":"PHASE1","title":"Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-05-31","conditions":"HER2-positive Breast Cancer","enrollment":28},{"nctId":"NCT05809752","phase":"PHASE1","title":"A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-08-22","conditions":"Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer","enrollment":18},{"nctId":"NCT07317154","phase":"PHASE1","title":"Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01","conditions":"Recurrent Respiratory Papillomatosis","enrollment":9},{"nctId":"NCT07020715","phase":"PHASE2","title":"A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2026-03-01","conditions":"Multiple Sclerosis","enrollment":14},{"nctId":"NCT07260058","phase":"PHASE1, PHASE2","title":"Immune Cell Therapy for Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.","startDate":"2025-12-01","conditions":"Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic), Colorectal Cancer (Locally Advanced or Metastatic)","enrollment":48},{"nctId":"NCT01697527","phase":"PHASE2","title":"Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2012-11-02","conditions":"Malignant Neoplasm","enrollment":6},{"nctId":"NCT05631899","phase":"PHASE1","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-04-03","conditions":"Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V","enrollment":9},{"nctId":"NCT05773859","phase":"PHASE1, PHASE2","title":"NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2023-03-17","conditions":"Epithelial Ovarian Cancer, Ovarian Carcinoma","enrollment":10},{"nctId":"NCT00510497","phase":"PHASE1, PHASE2","title":"Autologous Dendritic Cell Vaccine in HIV1 Infection","status":"COMPLETED","sponsor":"Sharon Riddler","startDate":"2007-07","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT06100705","phase":"PHASE2","title":"Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-12-20","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":26},{"nctId":"NCT02111941","phase":"EARLY_PHASE1","title":"Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-04-14","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm","enrollment":19},{"nctId":"NCT03396575","phase":"PHASE1","title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-07-17","conditions":"Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma","enrollment":11},{"nctId":"NCT03758625","phase":"PHASE1","title":"Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure","status":"COMPLETED","sponsor":"Sharon Riddler","startDate":"2019-01-02","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT06639074","phase":"PHASE2","title":"Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-11-08","conditions":"Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma","enrollment":78},{"nctId":"NCT04912765","phase":"PHASE2","title":"Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2021-04-15","conditions":"Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer","enrollment":60},{"nctId":"NCT06708936","phase":"EARLY_PHASE1","title":"KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Kousai Bio Co., Ltd.","startDate":"2025-10-01","conditions":"Clear Cell Renal Cell Carcinoma (ccRCC)","enrollment":12},{"nctId":"NCT06799026","phase":"PHASE1","title":"A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"David Avigan","startDate":"2025-01-31","conditions":"Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma","enrollment":25},{"nctId":"NCT04201873","phase":"PHASE1","title":"Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-01-08","conditions":"Recurrent Glioblastoma","enrollment":40},{"nctId":"NCT06715605","phase":"PHASE2","title":"A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS","status":"WITHDRAWN","sponsor":"University Hospital, Antwerp","startDate":"2025-04-30","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT01863108","phase":"PHASE1","title":"Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2013-06","conditions":"Melanoma, Tumor Vaccines, Effects of Immunotherapy","enrollment":9},{"nctId":"NCT06805656","phase":"PHASE2","title":"Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals","status":"NOT_YET_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2025-09-01","conditions":"Hiv, HIV I Infection","enrollment":70},{"nctId":"NCT04963413","phase":"PHASE1","title":"RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.","status":"TERMINATED","sponsor":"University of Florida","startDate":"2022-01-13","conditions":"Glioblastoma","enrollment":6},{"nctId":"NCT02775292","phase":"PHASE1","title":"Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2017-01-03","conditions":"Adult Solid Neoplasm, Childhood Solid Neoplasm, Metastatic Neoplasm","enrollment":1},{"nctId":"NCT04523688","phase":"PHASE2","title":"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2021-03-25","conditions":"Glioblastoma, Vaccination","enrollment":28},{"nctId":"NCT07068555","phase":"PHASE1, PHASE2","title":"Prostate Cancer Vaccines","status":"RECRUITING","sponsor":"Shenzhen Geno-Immune Medical Institute","startDate":"2025-06-15","conditions":"Prostate Cancer Indications","enrollment":30},{"nctId":"NCT05195619","phase":"PHASE1","title":"Personalized DC Vaccines in Non Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2022-03-22","conditions":"Non-small Cell Lung Cancer","enrollment":16},{"nctId":"NCT02143518","phase":"PHASE1","title":"Safety and Immunogenicity Study of Na-GST-1 With or Without CpG","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2014-10","conditions":"Hookworm Infection, Hookworm Disease","enrollment":24},{"nctId":"NCT00683670","phase":"PHASE1","title":"Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-08","conditions":"Melanoma","enrollment":17},{"nctId":"NCT03592888","phase":"PHASE1","title":"DC Vaccine in Pancreatic Cancer","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-11-20","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":29},{"nctId":"NCT06195618","phase":"PHASE1","title":"Personalized Vaccine for TNBC Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Universidad Nacional de Colombia","startDate":"2025-08-01","conditions":"Breast Cancer Female","enrollment":8},{"nctId":"NCT05920798","phase":"PHASE1, PHASE2","title":"Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-09-28","conditions":"Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma","enrollment":40},{"nctId":"NCT03970746","phase":"PHASE1, PHASE2","title":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"PDC*line Pharma SAS","startDate":"2019-09-10","conditions":"Non Small Cell Lung Cancer","enrollment":73},{"nctId":"NCT03035331","phase":"PHASE1, PHASE2","title":"Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-08-15","conditions":"Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":11},{"nctId":"NCT03600350","phase":"PHASE2","title":"pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2018-09-10","conditions":"Prostate Cancer","enrollment":19},{"nctId":"NCT05127824","phase":"PHASE2","title":"Autologous Dendritic Cell Vaccine in Kidney Cancer","status":"RECRUITING","sponsor":"Jodi Maranchie","startDate":"2023-07-06","conditions":"Carcinoma, Renal Cell","enrollment":42},{"nctId":"NCT04078269","phase":"PHASE1","title":"MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2019-08-26","conditions":"Non-small Cell Lung Cancer","enrollment":6},{"nctId":"NCT05964361","phase":"PHASE1, PHASE2","title":"First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-12-06","conditions":"Esophageal Cancer, Pancreas Cancer, Ovarian Cancer","enrollment":10},{"nctId":"NCT03688178","phase":"PHASE2","title":"DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Annick Desjardins, MD","startDate":"2020-08-26","conditions":"Glioblastoma","enrollment":43},{"nctId":"NCT01885702","phase":"PHASE1, PHASE2","title":"Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2010-10","conditions":"Colorectal Cancer","enrollment":25},{"nctId":"NCT06749925","phase":"PHASE3","title":"Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01","conditions":"Glioblastoma","enrollment":186},{"nctId":"NCT05714306","phase":"PHASE1, PHASE2","title":"PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2023-08-01","conditions":"Ovarian Carcinoma","enrollment":""},{"nctId":"NCT05749627","phase":"NA","title":"Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Nanchang University","startDate":"2023-04-01","conditions":"Advanced Malignant Solid Tumors","enrollment":20},{"nctId":"NCT04627246","phase":"PHASE1","title":"Personalized Vaccine with SOC Chemo Followed by Nivo in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2020-09-11","conditions":"Pancreatic Adenocarcinoma","enrollment":14},{"nctId":"NCT05457959","phase":"PHASE1","title":"Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-12-01","conditions":"Diffuse Hemispheric Glioma, H3 G34-Mutant","enrollment":""},{"nctId":"NCT06253234","phase":"PHASE1","title":"Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-02-02","conditions":"WHO Grade III Gliomas, WHO Grade IV Gliomas","enrollment":12},{"nctId":"NCT04968366","phase":"PHASE1","title":"Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-07-30","conditions":"Glioblastoma Multiforme of Brain","enrollment":11},{"nctId":"NCT06522919","phase":"PHASE2","title":"Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-01-07","conditions":"Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer","enrollment":36},{"nctId":"NCT01067287","phase":"PHASE2","title":"Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2010-03","conditions":"Multiple Myeloma","enrollment":35},{"nctId":"NCT02465268","phase":"PHASE2","title":"Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-08-09","conditions":"Glioblastoma Multiforme, Glioblastoma, Malignant Glioma","enrollment":175},{"nctId":"NCT03546361","phase":"PHASE1","title":"CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-07-08","conditions":"Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":24},{"nctId":"NCT01973322","phase":"PHASE2","title":"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized \"Proof-of-principle\" Phase II Study","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2013-10-08","conditions":"Malignant Melanoma of Skin Stage III, Malignant Melanoma of Skin Stage IV","enrollment":34},{"nctId":"NCT06752473","phase":"EARLY_PHASE1","title":"KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Kousai Bio Co., Ltd.","startDate":"2025-01-31","conditions":"Nasopharyngeal Carcinoma (NPC), EBV","enrollment":10},{"nctId":"NCT03092453","phase":"PHASE1","title":"Dendritic Cell Vaccination in Patients With Advanced Melanoma","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-05-01","conditions":"Melanoma","enrollment":5},{"nctId":"NCT02362464","phase":"PHASE2","title":"Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-05-12","conditions":"Prostatic Neoplasms, Neoplasms of Prostate, Prostate Cancer","enrollment":14},{"nctId":"NCT02618902","phase":"PHASE1","title":"A \"negative\"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2017-05-30","conditions":"Multiple Sclerosis","enrollment":9},{"nctId":"NCT02301611","phase":"PHASE2","title":"Phase IIB TL + YCWP + DC in Melanoma","status":"COMPLETED","sponsor":"Elios Therapeutics, LLC","startDate":"2015-01","conditions":"Melanoma","enrollment":187},{"nctId":"NCT01096602","phase":"PHASE2","title":"Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2010-05","conditions":"Acute Myelogenous Leukemia, AML","enrollment":63},{"nctId":"NCT06675201","phase":"PHASE2","title":"Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-10-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine, Immune Checkpoint Inhibitors (ICIs)","enrollment":165},{"nctId":"NCT05882305","phase":"EARLY_PHASE1","title":"KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial","status":"WITHDRAWN","sponsor":"Kousai Bio Co., Ltd.","startDate":"2023-06-10","conditions":"EBV-associated Lymphomas","enrollment":""},{"nctId":"NCT03546426","phase":"PHASE1","title":"Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2019-12-12","conditions":"Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer","enrollment":18},{"nctId":"NCT02649582","phase":"PHASE1, PHASE2","title":"Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2015-12","conditions":"Glioblastoma Multiforme of Brain","enrollment":20},{"nctId":"NCT04166006","phase":"PHASE2","title":"A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2019-12-12","conditions":"Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma","enrollment":51},{"nctId":"NCT03879512","phase":"PHASE1, PHASE2","title":"Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG","status":"COMPLETED","sponsor":"Wuerzburg University Hospital","startDate":"2018-02-07","conditions":"Childhood Glioblastoma","enrollment":24},{"nctId":"NCT02919644","phase":"PHASE2","title":"Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-12-02","conditions":"Stage IV Colorectal Cancer, Curative Resection","enrollment":19},{"nctId":"NCT01204684","phase":"PHASE2","title":"Dendritic Cell Vaccine for Patients With Brain Tumors","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2010-10-08","conditions":"Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma","enrollment":24},{"nctId":"NCT03371485","phase":"PHASE1","title":"AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Cancer Research UK","startDate":"2018-05-29","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":9},{"nctId":"NCT02061423","phase":"PHASE1","title":"HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-04-08","conditions":"Breast Cancer","enrollment":7}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"PYREXIA"},{"count":1,"reaction":"CARDIAC FAILURE"},{"count":1,"reaction":"DISEASE PROGRESSION"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"FLUID OVERLOAD"},{"count":1,"reaction":"GLIOBLASTOMA"},{"count":1,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":1,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":1,"reaction":"PRURITUS"},{"count":1,"reaction":"RASH MACULAR"}],"_approvalHistory":[],"publicationCount":608,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DC Vaccine","DCs"],"phase":"phase_3","status":"active","brandName":"Dendritic Cell Vaccine","genericName":"Dendritic Cell Vaccine","companyName":"Fundacion Clinic per a la Recerca Biomédica","companyId":"fundacion-clinic-per-a-la-recerca-biom-dica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A dendritic cell vaccine that activates the patient's immune system to recognize and attack cancer cells by presenting tumor-associated antigens. Used for Cancer (specific indication not publicly detailed for this Phase 3 program).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}